Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)

NCT01026415 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

73

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinomas
Disease, Hodgkin
Lymphoma, Large-Cell, Anaplastic
Lymphoma, Non-Hodgkin
Neoplasms

Interventions

DRUG: brentuximab vedotin
DRUG: rifampin
DRUG: midazolam
DRUG: ketoconazole
DRUG: brentuximab vedotin

Sponsor

Seagen Inc.

Collaborators

[object Object]